Promising prostate cancer drug gets extended trial for those already benefiting
Disease control
ENROLLING_BY_INVITATION
This trial gives men with metastatic castration-resistant prostate cancer (mCRPC) continued access to the experimental drug ZEN003694, often combined with enzalutamide (Xtandi), if they are already seeing benefits from it in a previous study. About 40 participants will be enrolle…
Phase: PHASE1, PHASE2 • Sponsor: Zenith Epigenetics • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC